Scilex Holding Company

Scilex Holding Company is a publicly traded biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company's mission is to become the global pain management leader, committed to responsible development of pharmaceutical products that maximize quality of life. Scilex currently markets three FDA-approved non-opioid pain management products: ZTlido® (lidocaine topical system) 1.8%, Gloperba® (colchicine USP) oral solution, and ElyxybTM (celecoxib) oral solution. Scilex is also developing a late-stage pipeline of non-opioid therapies, including SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (sciatica), SP-103 (lidocaine topical system) 5.4% for the treatment of low back pain, and SP-104 for the treatment of chronic pain and fibromyalgia.

Scilex is headquartered in Palo Alto, California, and operates in both Palo Alto and San Diego. The company is a majority-owned subsidiary of Sorrento Therapeutics, Inc. Scilex's leadership team has over 30 years of experience in the life science industry, leading product development and commercialization of innovative therapies and creating companies with documented success. The company is committed to social, environmental, economic, and ethical principles in the development of its products.

Scilex Holding Company offers a competitive benefits package to its employees that includes medical, dental, and vision insurance, life and disability insurance, an Employee Stock Purchase Plan (ESPP), a 401k plan, and paid holidays.

Scilex Holding Company is dedicated to the development and commercialization of non-opioid pain management products. They are committed to becoming the global leader in pain management, responsibly developing pharmaceutical products that maximize quality of life through social, environmental, economic, and ethical principles. Their mission is to advance non-opioid therapeutic options to treat acute and chronic pain in patients with the greatest unmet needs, harnessing the power of revolutionary delivery technologies to safely and effectively provide therapies to those who need them most.

Scilex Holding promotes a team-spirited and collaborative culture that values excellence, accountability, integrity, and diversity. They believe in fostering an atmosphere of innovation and pushing thinking further to find viable solutions for patients and providers through groundbreaking technologies. The company emphasizes a belief in the "law of science" and a commitment to healthy, pain-free lives for all.

Scilex Holding emphasizes a commitment to diversity, equity, and inclusion, striving to create a welcoming and collaborative environment where everyone feels valued and respected. Their company culture fosters a team-spirited approach that encourages open communication, embraces diverse perspectives, and values individual contributions. While specific details about their DEI initiatives are not explicitly stated on the website, their general mission statement and cultural description highlight a strong dedication to creating a workplace that prioritizes inclusivity and promotes a sense of belonging for all employees.